Coagulation and Haemorrhagic Disorders
Featured Learning Zones
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Fibrinogen Deficiency in Bleeding Learning Zone
Fibrinogen is an essential coagulation factor in the blood clotting cascade. The importance for fibrinogen in normal haemostasis is highlighted in patients of inherited fibrinogen deficiencies who display coagulopathies such as excessive bleeding and thrombolytic events.
The role of imaging in myeloma has gained increasing importance over the past few years. The recently revised definition of myeloma from the International Myeloma Working Group (IMWG) includes cross sectional imaging...
A growing population of long-term survivors of myeloma isnow accumulating the ‘late effects’ not only of myeloma itself, but also of several lines of treatment given throughout the course of the disease.
In this document, the term ‘peripheral arterial diseases’ encompasses all arterial diseases other than coronary arteries and the aorta. This should be clearly distinguished from the term ‘peripheral artery disease’...
Related news and insights
Gamida Cell Ltd.:announced positive topline results from its Phase III clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant The median time to neutrophil engraftment was 12 days for patients randomized to omidubicel compared to 22 days for the comparator group (p<0.001).
Alexion Pharmaceuticals announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorization in the European Union for Ultomiris (ravulizumab) for the treatment of patients with a body weight of 10 kg or above with atypical hemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received Soliris (eculizumab) for at least 3 months and have evidence of response to eculizumab.